Tesofensine
- Status
- Preclinical, , not approved for human use
- Evidence
Not graded on a research bench yet
Tesofensine (NS2330) is an orally-administered small-molecule triple monoamine reuptake inhibitor — it blocks the reuptake of noradrenaline, dopamine, and serotonin, placing it in the same broad pharmacologic class as sibutramine (withdrawn 2010 for cardiovascular risk) but with a different receptor-affinity profile and markedly longer half-life.
Reviewed
01Overview
What Tesofensine is
Originally developed by Danish company NeuroSearch in the late 1990s as a treatment for Alzheimer's disease and Parkinson's disease, tesofensine failed both neurology indications in Phase 2 trials. What rescued the compound from shelf-abandonment was an incidental observation across those failed neurology programs: patients consistently lost weight on tesofensine, often substantially, despite losing weight not being a primary or secondary endpoint.
Read the full overviewShow less
That signal triggered repositioning toward obesity, culminating in a 2008 Phase 2B trial (TIPO-1) published in The Lancet that remains one of the most-cited papers in modern obesity pharmacology (Astrup et al., 2008). The trial enrolled 203 obese adults randomized to tesofensine 0.25 mg, 0.5 mg, 1.0 mg daily or placebo plus a hypocaloric diet, and reported mean 24-week weight loss of 6.7%, 11.3%, and 12.8% at the three active doses vs 2.2% for placebo — roughly double what any other obesity drug was producing at the time and within striking distance of early bariatric surgery results. The magnitude of the effect generated substantial commercial interest and positioned tesofensine as potentially the first "surgery-competitive" weight-loss drug.
However, the 1 mg dose produced clinically meaningful increases in heart rate and blood pressure, raising the cardiovascular safety concerns that had already led to sibutramine's withdrawal. FDA and EMA did not approve tesofensine, and the Phase 3 program stalled. NeuroSearch divested the compound to Saniona (Danish biotech), whose partner Medix ran a Phase 3 trial in Mexico and applied to COFEPRIS, the Mexican regulator, for approval in obesity. Saniona's report of 27 August 2026 says Medix is still seeking that approval, so tesofensine is not approved in Mexico or anywhere else. Tesomet, Saniona's tablet that combines tesofensine with metoprolol, is an investigational drug that has completed Phase 2 trials in hypothalamic obesity and Prader-Willi syndrome; it is not approved anywhere either. Tesofensine has since become a widely-traded research chemical, with unapproved-market use for weight loss despite the unresolved cardiovascular signal and limited Phase 3 safety data.
Cross-references include Semaglutide and Tirzepatide (approved GLP-1-class alternatives with stronger safety profiles), Retatrutide (investigational triple agonist), Orforglipron (oral GLP-1 agonist), Cagrilintide (amylin analog), and AOD-9604 (another repurposed failure). For stimulant-class cognitive context see Modafinil and Methylphenidate.
How it works
Tesofensine blocks the presynaptic reuptake of three monoamine neurotransmitters: noradrenaline (norepinephrine), dopamine, and serotonin. By inhibiting the neurotransmitter transporters (NET, DAT, and SERT respectively), tesofensine raises synaptic concentrations of all three monoamines, producing a combined stimulant, pro-motivational, and mildly anti-depressive signature.
Read the full mechanismShow less
Receptor Affinities (Preclinical Characterization): Rodent and human receptor-binding studies have characterized tesofensine's affinity profile at the three monoamine transporters ([Axel et al., 2010]):
- NET (noradrenaline transporter): highest affinity; potent inhibition
- DAT (dopamine transporter): intermediate affinity
- SERT (serotonin transporter): moderate affinity
- Relative balance: NET > DAT > SERT, which distinguishes tesofensine from classical SSRIs (SERT-selective) and from most ADHD stimulants (NET/DAT-preferring without serotonin involvement)
The combined monoamine elevation produces several downstream effects relevant to weight loss:
Appetite Suppression Mechanisms:
- Mesolimbic dopamine elevation reduces the hedonic drive toward palatable food. Much of modern ad-libitum overeating is reward-driven rather than homeostatic hunger-driven; amplifying endogenous dopamine tone reduces the perceived reward of the next bite, which self-limits intake even when food is freely available.
- Hypothalamic noradrenaline activity suppresses orexigenic (hunger-producing) signaling, particularly NPY/AgRP neuronal activity in the arcuate nucleus. This is believed to be the dominant mechanism by which NE-heavy monoamine drugs reduce appetite — it's the same hypothalamic locus where leptin acts.
- Serotonin elevation contributes to satiety signaling via 5-HT2C receptor activation in the hypothalamus. This is the same receptor that lorcaserin (withdrawn from market 2020) was designed to selectively activate.
- Delayed gastric emptying and enhanced thermogenesis: documented in dedicated energy-balance studies of tesofensine, contributing to caloric deficit beyond simple appetite reduction ([Sjödin et al., 2010]).
Motivational and Cognitive Effects: Beyond appetite effects, the NE/DA combination produces stimulant-like subjective effects similar in character (though not identity) to low-dose ADHD medications: increased alertness, reduced fatigue, enhanced concentration, and sometimes mood elevation. In clinical trials these effects were reported positively by many patients and contributed to the "quality of life improvement" endpoint that also favored tesofensine.
Pharmacokinetic Profile:
- Oral bioavailability: high (~100% in fasted state)
- Time to peak plasma (Tmax): ~8 hours
- Half-life: ~9 days (extremely long for an oral small molecule — one of tesofensine's defining pharmacokinetic features)
- Steady state: reached after ~4-6 weeks of daily dosing — full effect does not emerge immediately, and dose changes take weeks to fully express
- Metabolism: hepatic, primarily CYP3A4; active metabolite NS2360 with similar activity
- Excretion: renal, with a long terminal elimination phase
The 9-day half-life is pharmacokinetically unusual and has important clinical implications: (1) once-daily dosing is pharmacologically redundant — actual trough-to-peak fluctuation is minimal across dosing intervals; (2) any dose change takes 4-6 weeks to reach new steady state, so titration is slow; (3) drug discontinuation produces a gradual decline over several weeks, which is protective against acute discontinuation syndromes but also means residual effect persists long after stopping; (4) drug-drug interaction considerations extend weeks after discontinuation because tesofensine remains in the system.
Cardiovascular Pharmacology (The Key Safety Question): Monoamine reuptake inhibition in peripheral noradrenergic synapses produces sympathetic activation with measurable increases in heart rate and blood pressure. In the Phase 2B key trial, the 1 mg dose produced:
- Heart rate increase: ~7.5 bpm vs placebo
- Systolic blood pressure increase: ~2 mmHg vs placebo (not statistically significant but trended)
- Diastolic blood pressure: similar trend
These are small on individual patient level but meaningful at population level given the association between chronic heart rate elevation and cardiovascular events. The sibutramine precedent looms large here: sibutramine's SCOUT trial (11,000+ high-CV-risk patients) showed a 16% increased rate of non-fatal MI and non-fatal stroke despite effective weight loss, leading to global withdrawal. Tesofensine has not been tested in a comparable cardiovascular outcomes trial, and regulators have not been willing to approve it for broad obesity indication without one.
Cross-Class Comparison:
- vs Semaglutide (GLP-1): completely different mechanism (incretin pathway, no monoamines); Phase 3 evidence in ~4,500 patients per trial vs tesofensine's ~200; favorable cardiovascular profile; FDA-approved.
- vs Tirzepatide (GLP-1/GIP): similar magnitude weight loss (20-22%) with cardiovascular safety established in SURPASS-CVOT; FDA-approved.
- vs Retatrutide (GLP-1/GIP/glucagon): 24% weight loss at 48 weeks, also well-tolerated cardiovascularly; Phase 3 ongoing.
- vs phentermine: phentermine is a single-transporter NE-releasing agent with shorter half-life (~24 hours). Similar appetite-suppression mechanism but more acute and less metabolically active. FDA-approved for short-term use only.
- vs sibutramine (withdrawn): closest pharmacologic relative; similar appetite suppression magnitude; sibutramine's withdrawal is the critical precedent shaping tesofensine's regulatory fate.
Benefits listed
- Significant weight loss (10-15% body weight)
- Appetite suppression
- Increased metabolic rate
- Enhanced dopamine-driven motivation
02Research
Free with emailWhat the research shows
No research bench grades Tesofensine yet. Benches compare compounds people pair, with the evidence for each.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
Tesofensine side effects and interactions
Side effects
Not in our record
Who should not use it
Contraindications
Absolute Contraindications (Do Not Use):
- Concurrent MAOI use (within 14 days — longer for transdermal selegiline): risk of hypertensive crisis, serotonin syndrome
- Known hypersensitivity to tesofensine or any formulation component
- Active cardiovascular disease: recent MI, unstable angina, uncontrolled arrhythmia, decompensated heart failure
- Uncontrolled hypertension (BP persistently >160/100)
- Pheochromocytoma: sympathetic activation contraindicated
- Severe hepatic impairment (Child-Pugh C)
- End-stage renal disease
- Pregnancy: no safety data; monoamine reuptake inhibitors as a class have concerning signals
- Active substance use disorder with stimulants (cocaine, methamphetamine): additive CV risk, potential for misuse
- Concurrent use of sibutramine (where still available) or other triple/dual monoamine reuptake inhibitors
Read all the contraindications and cautionsShow less
Relative Contraindications (Use with Significant Caution):
- Controlled hypertension: baseline BP at upper end of normal; requires close monitoring
- Mild-moderate heart failure: case-by-case
- Arrhythmia history (even if currently stable)
- Psychiatric conditions:
- Bipolar disorder (risk of mania induction)
- Generalized anxiety disorder (risk of exacerbation)
- History of psychosis
- Concurrent SSRI/SNRI use: serotonin syndrome risk; case-by-case with low doses and close monitoring
- Elderly (>65): lower starting doses, more gradual titration, enhanced monitoring
- Hepatic impairment (Child-Pugh B): dose reduction; close monitoring
- Renal impairment (moderate to severe): dose reduction
- History of seizures: monoamine enhancement may lower seizure threshold
- Narrow-angle glaucoma: sympathetic activation may precipitate acute angle-closure
- Prostatic hyperplasia with urinary retention: sympathetic effects may worsen
Drug-Specific Interaction Contraindications:
Absolute Avoid:
- MAOIs (phenelzine, tranylcypromine, selegiline at AD doses, isocarboxazid, moclobemide)
- Linezolid (reversible MAOI activity)
- IV methylene blue (MAOI-A activity)
- Sibutramine, other triple/dual monoamine reuptake inhibitors
- Cocaine, amphetamine (recreational)
Avoid or Extreme Caution:
- Other serotonergic agents: SSRIs, SNRIs, tricyclic antidepressants, trazodone, tramadol, meperidine, fentanyl, dextromethorphan, St. John's Wort
- Triptans (sumatriptan etc.)
- Lithium
- MDMA (recreational)
Caution with Dose Adjustment:
- CYP3A4 strong inhibitors: ketoconazole, itraconazole, clarithromycin, ritonavir — reduce tesofensine dose
- CYP3A4 strong inducers: rifampin, phenytoin, carbamazepine, St. John's Wort — may reduce tesofensine efficacy
- Beta-blockers: clinically useful combination (reduces HR elevation) but monitor for bradycardia at higher doses
- Thyroid hormones: may compound CV effects at supraphysiologic doses
- Other weight loss agents: redundancy and additive risk
Special Populations and Situations:
Pre- and Peri-operative: Discontinue tesofensine at least 2 weeks before elective surgery due to:
- CV effects (intraoperative hemodynamic concerns)
- Anesthetic interactions (particularly with halothane, though rarely used modernly)
- Serotonergic interactions with analgesics (especially meperidine, fentanyl, tramadol)
- Given 9-day half-life, "2 weeks" is actually shorter than ideal; ≥4 weeks is more complete but often impractical
Alcohol: Not absolute contraindication but:
- Alcohol amplifies sedative effects minimally but amplifies hepatic CYP3A4 burden
- Worsens sleep disruption from tesofensine
- Adds CV stress
- Recommendation: minimize or eliminate alcohol during treatment
Caffeine: Not contraindication but:
- Additive cardiac stimulant effect
- Worse sleep compounding
- Recommendation: limit to moderate caffeine (≤200 mg/day) during tesofensine use
Concurrent Conditions Requiring Extra Monitoring:
- Diabetes: tesofensine weight loss improves glycemic control — monitor for hypoglycemia in insulin-treated patients
- Thyroid disorders: can compound CV effects
- COPD: caution with sympathetic effects on cardiac rhythm
- Seizure disorder: seizure threshold lowered
- ADHD on medication: stimulant redundancy
- Depression on medication: serotonergic interaction risk
- Anxiety disorder: may worsen
Contraindicated Populations by Age:
- Pediatric (<12): not studied
- Adolescent (12-17): studied in Prader-Willi only; general use not indicated
- Adult (18-65): primary population
- Elderly (>65): use with caution, lower starting dose
- Very elderly (>75): generally avoid unless specific circumstances justify
Discontinuation Criteria: Immediate discontinuation indicated if:
- New chest pain, especially with activity
- Palpitations with syncope or near-syncope
- Severe hypertension (>180/120 on any reading)
- Arrhythmia on ECG
- Signs of serotonin syndrome
- New or worsening psychiatric symptoms (mania, psychosis, severe anxiety)
- Pregnancy confirmed
- Preparation for surgery (2+ weeks before)
- Starting MAOI
- Significant weight loss to below healthy BMI
Warning Signs Requiring Medical Consultation:
- Gradual heart rate increase (>10 bpm over baseline)
- Gradual blood pressure increase (>10 mmHg systolic)
- Worsening sleep
- Mood changes
- New medication combinations
- Sudden significant weight change (too fast or stalling)
- Any symptoms concerning for cardiovascular, serotonergic, or psychiatric effects
Overdose: Tesofensine overdose presents with:
- Tachycardia, hypertension
- Agitation, tremor
- Potential for serotonin syndrome signs
- Seizures in severe overdose
- Arrhythmia risk
No specific antidote. Supportive care:
- ICU monitoring for CV effects
- Benzodiazepines for agitation/serotonin features
- Cooling for hyperthermia
- Cyproheptadine historically for serotonin syndrome (evidence limited)
- Activated charcoal within 1-2 hours if ingestion recent and airway protected
- Given 9-day half-life, elimination is prolonged — prepare for extended supportive care
Interactions
4 pairings in our record: 2 to avoid and 2 with a caution.
SSRIs
AvoidTesofensine inhibits serotonin reuptake — risk of serotonin syndrome
MAOIs
AvoidDangerous hypertensive crisis risk
Semaglutide
CautionBoth suppress appetite strongly — risk of excessive weight loss and malnutrition
Tirzepatide
CautionOverlapping appetite suppression — requires careful monitoring
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailTesofensine dosage and protocols
- Dose range
- 0.25 mg - 1 mg daily (oral)
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
- Stacking notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
Tesofensine prices
2 listings from 2 vendors, opening in the Featured order.
- Pack prices
- $79.99 to $109.99
- Lowest per mg
- $2.67/mg
- Vendors
- 2
- Listings
- 2 (capsule)
Prices as the vendors list them, last recorded 22 September 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
Tesofensine Capsules 60ct capsule, 60 capsules In stock | $2.67/mg $79.99 Lowest per mg | Buy Tesofensine Capsules 60ct at ResearchChemHQ | |
Tesofensine capsule, 60 dry-fill units In stock | $3.67/mg $109.99 | Buy Tesofensine at BHG Labs |
Vendors selling Tesofensine(2: trust score, certificates, payment, shipping)
- ResearchChemHQ1 listing, from $79.99
Trust Score 100/100, 6 of 6 certificate records read, pays by card, crypto, ships to the US
- BHG Labs1 listing, from $109.99
Trust Score 100/100, 41 of 43 certificate records read, pays by card, crypto, ships to the US
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
06Chemistry
Chemistry and structure
- Molecular formula
- C17H23Cl2NO
- Molecular mass
- 328.3 g/mol
- CAS number
- 195875-84-4
- IUPAC name
- (1R,2S,3R,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-azabicyclo[3.2.1]octane
08Questions
Frequently asked questions
Is tesofensine approved by the FDA?
No. Tesofensine is not FDA-approved for any indication. It was never approved for obesity in the US or EU despite encouraging Phase 2B trial data (Astrup et al., 2008) because of unresolved cardiovascular safety concerns — specifically heart rate and blood pressure elevation at effective doses. The sibutramine precedent (withdrawn globally in 2010 after its SCOUT trial showed increased cardiovascular events) weighs heavily on tesofensine's regulatory status. It is not approved in Mexico either: Saniona's partner Medix has applied to the Mexican regulator for approval in obesity, and Saniona's report of 27 August 2026 says Medix is still seeking it. Tesomet, a tablet that combines tesofensine with metoprolol, is an investigational drug that has completed Phase 2 trials. In the US market, tesofensine circulates primarily as a 'research chemical' through online suppliers, with no regulatory oversight of quality, dosing, or use. For evidence-based weight loss, Semaglutide, Tirzepatide, and Orforglipron have FDA approval with stronger safety profiles.
How much weight loss can I actually expect on tesofensine?
Based on the pivotal Phase 2B TIPO-1 trial (24 weeks, 203 obese adults, concurrent hypocaloric diet), mean weight loss was: placebo 2.2%, tesofensine 0.25 mg 6.5%, tesofensine 0.5 mg 11.3%, tesofensine 1.0 mg 12.8% (Astrup et al., 2008). Placebo-adjusted that's roughly 4-11% weight loss depending on dose. These are averages with substantial individual variability. Key caveats: (1) the trial was 24 weeks — longer-term durability data is limited; (2) the data reflects patients in a medically-supervised trial with adherence monitoring, dietary counseling, and real drug (quality-assured). Research chemical users may see different outcomes due to dose variability and lack of lifestyle structure; (3) for comparison, Semaglutide at 68 weeks produces ~15%, Tirzepatide at 72 weeks produces ~20%. Tesofensine's 12-13% at 24 weeks is impressive for the duration but GLP-1 class has surpassed it in absolute magnitude over longer trials.
Why is the cardiovascular concern such a big deal?
Because the class history is bad. Sibutramine (Meridia) was a closely related dual monoamine reuptake inhibitor approved in the late 1990s for obesity. It worked — produced roughly 5% placebo-adjusted weight loss. But in 2010, the SCOUT trial (11,000+ patients with cardiovascular risk factors) showed a 16% increased rate of non-fatal MI, non-fatal stroke, and CV death with sibutramine vs placebo, even though the trial excluded patients with the highest CV risk. This led to global withdrawal. Tesofensine's pharmacology overlaps substantially with sibutramine (both are monoamine reuptake inhibitors with appetite suppression mechanism), and tesofensine produces measurable HR elevation (~7 bpm at 1 mg dose) in its trials. Regulators have not been willing to approve tesofensine for broad obesity indication without a comparable CV outcomes trial to establish safety. That trial would need to enroll 10,000+ patients and run 3-5 years; it has not been conducted. Until it is, tesofensine's cardiovascular profile at population level is genuinely unknown.
How does tesofensine compare to semaglutide or tirzepatide?
Completely different mechanisms. Tesofensine is a triple monoamine reuptake inhibitor — it boosts noradrenaline, dopamine, and serotonin in the brain, producing appetite suppression and mild thermogenesis. Semaglutide and Tirzepatide are GLP-1 (and GIP for tirzepatide) receptor agonists — they activate incretin receptors in the hypothalamus and brainstem, producing appetite suppression, delayed gastric emptying, and improved glycemic control. Head-to-head comparisons have not been conducted, but based on separate trials: semaglutide produces ~15% weight loss at 68 weeks, tirzepatide ~20% at 72 weeks, tesofensine ~12-13% at 24 weeks (longer-term tesofensine data limited). GLP-1 class has extensive cardiovascular outcomes trial data showing either neutral or favorable CV effects. Tesofensine has unresolved CV safety. GI side effects are prominent with GLP-1 class (nausea, diarrhea) while tesofensine has stimulant-type side effects (insomnia, dry mouth, palpitations). Injection (GLP-1) vs oral (tesofensine) is another practical difference. For most patients, GLP-1 class should be tried first given the safety profile; tesofensine is a second-line consideration for specific situations.
What's the deal with research chemical tesofensine?
Tesofensine sold online as a 'research chemical' is typically manufactured in the same overseas labs that produce other research-chemical weight loss products. Quality varies substantially: independent batch testing has shown dose accuracy ranging from ~50% to ~150% of label claim, with contamination and degradation concerns depending on vendor. Legal status in the US: tesofensine is unscheduled federally (not a controlled substance), but it's not an FDA-approved drug, so sale for human consumption is technically illegal. Research chemical vendors use 'not for human consumption' labeling as legal cover. Practical reality: many people consume it, but without the quality controls, dose accuracy, or medical supervision that would apply to an approved pharmaceutical. Risks: (1) unknown dose per capsule means unknown efficacy and unknown risk; (2) no medical oversight for cardiovascular monitoring; (3) no drug-drug interaction screening; (4) no psychiatric screening. If you're considering research chemical tesofensine, at minimum get a batch-level third-party COA (HPLC + mass spec), start at below-label doses, and arrange independent cardiovascular monitoring. Better: pursue regulated alternatives.
Can I combine tesofensine with semaglutide for faster weight loss?
Pharmacologically possible — the mechanisms don't overlap — but this combination is not formally studied and has specific concerns. Tesofensine provides monoamine-based appetite suppression with CV side effects. Semaglutide provides GLP-1-based appetite suppression with GI side effects. In theory, additive weight loss is plausible. In practice: (1) combined side effect burden (stimulant + GLP-1 nausea) is taxing; (2) aggressive weight loss exceeds what most patients can handle nutritionally without lean mass loss; (3) cardiovascular monitoring becomes essential — GLP-1 drugs don't amplify tesofensine's CV signal directly but rapid weight loss itself can produce BP/HR changes; (4) drug cost and logistics multiply. If attempted, the reasonable approach: establish stable tesofensine (0.5 mg) for several weeks with clean CV monitoring, then add lowest-dose semaglutide (0.25 mg weekly) with slow titration; never escalate both simultaneously; continuous CV monitoring. In most cases, picking one drug and maximizing it is clinically wiser than dual therapy — Tirzepatide monotherapy at 15 mg achieves ~22% weight loss without tesofensine's CV baggage.
Does tesofensine affect mood or cognition?
Yes, both. Tesofensine's triple monoamine reuptake inhibition produces stimulant-like cognitive effects similar in character (though not identity) to low-dose ADHD medications: increased alertness, improved concentration, reduced fatigue, mild antidepressant-like mood elevation. In clinical trials, 'quality of life' endpoints favored tesofensine vs placebo, partly because of these effects. The cognitive effects are noticeable within days and sustained during treatment. Downsides: (1) insomnia is common — the long 9-day half-life means even morning dosing produces some evening stimulant exposure; (2) anxiety can emerge or worsen, particularly in patients with underlying anxiety conditions; (3) irritability is reported at higher doses; (4) mania/hypomania risk in patients with bipolar spectrum disorder — this is a significant contraindication. The cognitive profile is often subjectively positive but should not be confused with cognitive enhancement as a primary goal — tesofensine is an obesity drug with cognitive side effects, not a nootropic. If cognitive effects are the primary goal, Modafinil or stimulant medications (methylphenidate, amphetamine) have better evidence bases and lower CV risk profiles for that specific indication.
What happens when I stop tesofensine?
Because of the 9-day half-life, tesofensine plasma levels decline gradually over 4-6 weeks after the last dose — not acutely. There is no classic withdrawal syndrome: no rebound depression, no acute discontinuation effects, no physical withdrawal symptoms. What does happen: (1) appetite returns gradually as plasma levels drop; (2) weight regain begins and typically accelerates if lifestyle structure isn't in place; (3) heart rate and blood pressure gradually return to baseline; (4) sleep normalizes; (5) any subjective stimulant effects fade. Weight regain after discontinuation is near-universal without sustained behavioral intervention — this is true of virtually all weight loss pharmacology, not tesofensine specifically. Plan for it: (1) establish sustainable dietary patterns during active treatment; (2) maintain resistance training throughout and after; (3) consider bridging to GLP-1 class if long-term pharmacotherapy is clinically indicated; (4) avoid sudden caloric rebound. Drug interaction considerations persist for ~4-6 weeks after discontinuation — do not start MAOIs, serotonergic agents, or other contraindicated drugs immediately after stopping tesofensine.
Is there any role for tesofensine in long-term use?
The honest answer is: evidence for long-term use (>52 weeks) is limited. Published controlled trial data extends primarily to 24 weeks with some 48-week extension data in subsets. Tesofensine has never been approved or marketed, so no post-marketing safety data exist. Long-term concerns with tesofensine include: (1) cardiovascular trajectory — the CV signal established in short-term trials could accumulate to clinically meaningful events over years; (2) sympathetic nervous system adaptation and whether sustained HR elevation leads to cardiac remodeling; (3) tolerance development — some patients report need for dose increase at 12-18 months to maintain appetite suppression; (4) psychiatric effects over years of continuous monoamine enhancement; (5) drug-drug interaction management in aging patients who accumulate medications. Realistic long-term strategies: (1) intermittent use (12-16 weeks on, 4-6 weeks off) leverages long half-life for gradual on/off transitions; (2) dose reduction to maintenance levels (0.25 mg) after initial weight loss phase; (3) transition to GLP-1 class for sustained pharmacotherapy; (4) accept weight regain and discontinuation when CV or other concerns emerge. For most patients, tesofensine is best thought of as a 12-24 month intervention in a broader weight management strategy, not a lifetime medication.
Who should definitely NOT take tesofensine?
Absolute contraindications: (1) Anyone currently on an MAOI or within 14 days of stopping one — hypertensive crisis and serotonin syndrome risk; (2) Recent MI, unstable angina, uncontrolled arrhythmia, or decompensated heart failure — sympathetic activation can be catastrophic; (3) Uncontrolled hypertension (BP persistently >160/100); (4) Pheochromocytoma; (5) Pregnancy — no safety data and concerning class signals; (6) Active substance use disorder with stimulants — additive CV risk and misuse potential; (7) Severe hepatic impairment (Child-Pugh C) or end-stage renal disease — clearance impairment amplifies exposure given already long half-life. Relative contraindications (use only with significant caution and specialist oversight): elderly patients (>65), mild-to-moderate hypertension, arrhythmia history, bipolar disorder (mania risk), severe anxiety disorders, concurrent SSRI/SNRI use, history of seizures, narrow-angle glaucoma. For patients without contraindications but without specific benefit: if you don't have obesity meeting pharmacotherapy indication (BMI ≥30, or ≥27 with comorbidities) and haven't failed or been intolerant of safer alternatives like GLP-1 class, tesofensine is not a reasonable choice. It's not a lifestyle drug or a 'trying to lose 10 pounds for summer' drug — the risk-benefit calculus requires genuine clinical indication.
How many vendors sell Tesofensine, and what does it cost per mg?
2 of the vendors BodyHackGuide tracks list Tesofensine (2 listings). Among BodyHackGuide's Tesofensine listings recorded as in stock with a milligram count, the lowest price per milligram is $2.67/mg at ResearchChemHQ and the median is $3.17/mg. The Tesofensine prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Tesofensine listing is dated 22 September 2026.
Which vendors have third-party COAs for Tesofensine on file at BodyHackGuide?
BodyHackGuide holds 20 third-party certificate records for Tesofensine, from BHG Labs. An editor has read 1 of BodyHackGuide's 20 certificate records for Tesofensine and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's Tesofensine certificate records are ILS Laboratories and Freedom Diagnostics Testing, and the newest test date on them is 18 September 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Related
Articles on Tesofensine
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

